Already have an ACS ID? Log in
Renew your membership, and continue to enjoy these benefits.
Already an ACS Member? Log in here
Choose the membership that is right for you. Discount will be applied automatically at checkout.
Enjoy these benefits no matter which membership you pick.
Most Popular in Business
Johnson & Johnson and Gilead Sciences are investing in therapies that treat B-cell malignancies. J&J will invest $75 million in MacroGenics and pay the biotech firm a $50 million fee to license MGD011, a monoclonal antibody in preclinical development as a treatment for B-cell blood cancers. The antibody is designed to redirect cancer-fighting T cells to eliminate CD19-expressing cells found in many such cancers. Separately, Gilead will license Ono Pharmaceutical’s ONO-4059, a small-molecule Bruton’s tyrosine kinase inhibitor for the treatment of B-cell malignancies including chronic lymphocytic leukemia. Gilead isn’t disclosing its payments to the Japanese firm.
This article has been sent to the following recipient: